The effect of pediatric rare diseases on retention rates for commercial health insurers has not been well studied. Insurers, policymakers, and government agencies in the United States may find it useful to have an accurate expectation for the length of enrollment by subscribers with a dependent who suffers from a pediatric rare disease and may be a candidate for a regenerative therapy with a potentially prolonged benefit. This paper aims to develop estimates for subscriber retention by a commercial insurer for up to 10 years.
This report was commissioned by AveXis and published by the Journal of Managed Care & Specialty Pharmacy.
Read or print the article